Xbrane Biopharma AB (publ) (XBRANE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everybody. My name is Martin. I'm the CEO of X-Brain and I'm here together with Jane, our CFO. So we will go through the highlights of our Q1 report 2026. I will start with an operational update and Jane will thereafter go through the financials. So we will start with Eximluci, our Lucentis biosimilar, and we will then go through some highlights in relation to Extivain, our Optivo biosimilar candidate under development. SimluSim is launched across 24 countries in Europe and the Middle East. It's a product which we have partnered with Stada. Stada is commercializing the product across these different countries. And it's a quite simple setup where we share the profit contribution post production cost and sales and marketing expenses 50-50. It's a sizable addressable market if we look at it as anti-VGF products for retinal disorders. We have of course then Lucentis and the Lucentis biosimilars. That's the dark blue chunk in the bottom of this graph on the left hand side. Active ingredient Ranibizumab and then we have Other competing molecules, ILEA and VABUSMO, and some off-label usage of the cancer drug Avastin. But it's all in all a market opportunity of 5 billion euro, which is growing on the back of an elderly population driving increase the need for these kind of drugs and also to some extent more cost-efficient options coming to the market within the Renovismab or Lucentis biosimilars as well as ILEA biosimilars. Looking now specifically on Xim Lucy and the performance last quarter, important to note is that we have a constant cash profit sharing coming in in Q1 2026 in relation to fourth quarter of 2025. So we'll see a little bit later in the presentation when Jane go through cash flow that we had 13 million swedish crowns coming in um cash wise this quarte...